NASDAQ:UMRX - Unum Therapeutics Stock Price, Price Target & More

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Unum Therapeutics Inc (NASDAQ:UMRX) posted its earnings results on Monday, May, 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.31. The firm had revenue of $2.22 million for the quarter, compared to analyst estimates of $2.45 million. View Unum Therapeutics' Earnings History.

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Unum Therapeutics.

4 equities research analysts have issued 12 month price objectives for Unum Therapeutics' stock. Their predictions range from $18.00 to $21.00. On average, they expect Unum Therapeutics' stock price to reach $19.6667 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View Analyst Ratings for Unum Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Unum Therapeutics include PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX), Innoviva (INVA), TherapeuticsMD (TXMD), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), Theravance Biopharma (TBPH), Amneal Pharmaceuticals (AMRX) and Uniqure (QURE).

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Unum Therapeutics' lock-up period expires on Tuesday, September 25th. Unum Therapeutics had issued 5,770,000 shares in its initial public offering on March 29th. The total size of the offering was $69,240,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Media coverage about UMRX stock has trended somewhat negative recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Unum Therapeutics earned a news sentiment score of -0.01 on Accern's scale. They also gave news coverage about the company an impact score of 44.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $14.06.

Unum Therapeutics has a market capitalization of $412.08 million and generates $8.36 million in revenue each year. Unum Therapeutics employs 53 workers across the globe.

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]